Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of aminobenzenesulfonamides. It features a thiazolo-indole core structure linked via a methylamine bridge to a pyridine-substituted benzenesulfonamide. The molecule has been studied as an experimental agent and is not approved for clinical use. Its primary mechanism of action is as an inhibitor of cyclin-dependent kinase 2 (CDK2), which plays a key role in cell cycle regulation and proliferation. Inhibition of CDK2 can induce cell cycle arrest and apoptosis in cancer cells; thus this compound has been investigated for potential anticancer activity. No marketed products or advanced clinical development are reported for this agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-[(7-oxo-7H-thiazolo[5,4-e]indol-8-ylmethyl)-amino]-N-pyridin-2-yl-benzenesulfonamide.